171 related articles for article (PubMed ID: 17478614)
1. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
Kogan NM; Schlesinger M; Peters M; Marincheva G; Beeri R; Mechoulam R
J Pharmacol Exp Ther; 2007 Aug; 322(2):646-53. PubMed ID: 17478614
[TBL] [Abstract][Full Text] [Related]
2. In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin).
Ryu JS; Lee HS; Hong YS; Lee JJ; Sohn UD; Kim TY
Cancer Chemother Pharmacol; 2006 Jun; 57(6):811-8. PubMed ID: 16175393
[TBL] [Abstract][Full Text] [Related]
3. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
5. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic treatment of xenograft Spirocerca lupi-associated sarcoma in a murine model.
Stettner N; Ranen E; Dank G; Lavy E; Brenner O; Harmelin A
Comp Med; 2007 Jun; 57(3):267-71. PubMed ID: 17605341
[TBL] [Abstract][Full Text] [Related]
7. Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts.
Hardman WE; Avula CP; Fernandes G; Cameron IL
Clin Cancer Res; 2001 Jul; 7(7):2041-9. PubMed ID: 11448922
[TBL] [Abstract][Full Text] [Related]
8. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
van Acker FA; Boven E; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
Clin Cancer Res; 2001 May; 7(5):1378-84. PubMed ID: 11350909
[TBL] [Abstract][Full Text] [Related]
9. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
Wang YM; Hu LX; Liu ZM; You XF; Zhang SH; Qu JR; Li ZR; Li Y; Kong WJ; He HW; Shao RG; Zhang LR; Peng ZG; Boykin DW; Jiang JD
Clin Cancer Res; 2008 Oct; 14(19):6218-27. PubMed ID: 18829501
[TBL] [Abstract][Full Text] [Related]
10. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
Ren Y; Wang Y; Zhang Y; Wei D
Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
[TBL] [Abstract][Full Text] [Related]
11. Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
Bast A; Kaiserová H; den Hartog GJ; Haenen GR; van der Vijgh WJ
Cell Biol Toxicol; 2007 Jan; 23(1):39-47. PubMed ID: 17063376
[TBL] [Abstract][Full Text] [Related]
12. The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat.
Rahimi Balaei M; Momeny M; Babaeikelishomi R; Ejtemaei Mehr S; Tavangar SM; Dehpour AR
Eur J Pharmacol; 2010 Sep; 641(2-3):193-8. PubMed ID: 20534381
[TBL] [Abstract][Full Text] [Related]
13. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
14. Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice.
Santucci L; Mencarelli A; Renga B; Ceccobelli D; Pasut G; Veronese FM; Distrutti E; Fiorucci S
Anticancer Drugs; 2007 Oct; 18(9):1081-91. PubMed ID: 17704659
[TBL] [Abstract][Full Text] [Related]
15. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin and doxorubicin in nude mice bearing human tumour xenografts.
Ford CH; Richardson VJ; Pushpanathan C; Ali SK
Anticancer Res; 1991; 11(5):1855-62. PubMed ID: 1768056
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
18. The influence of doxorubicin and 4'-epi-doxorubicin on lipid peroxidation in mouse heart, lungs and liver. Part II.
Pierściński G; Drzewoski J; Nowak D
Pol J Pharmacol; 1994; 46(1-2):55-9. PubMed ID: 7981772
[TBL] [Abstract][Full Text] [Related]
19. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model.
Kratz F; Roth T; Fichiner I; Schumacher P; Fiebig HH; Unger C
J Drug Target; 2000; 8(5):305-18. PubMed ID: 11328658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
